公开(公告)号：US20200255375A1

公开(公告)日：2020-08-13

申请号：US16858319

申请日：2020-04-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pravin Sudhakar Shirude ,  Vishweshwaraiah Baligar ,  Balaji Seshadri ,  Amit Kumar Chattopadhyay ,  Nicholas R. Wurtz ,  Ellen K. Kick

IPC: C07D207/14 ,  C07D403/12 ,  A61P9/04 ,  C07D409/12 ,  C07D413/10 ,  A61P9/10 ,  C07D401/12 ,  C07D401/10 ,  C07D403/10 ,  C07D413/14 ,  C07D417/10 ,  C07F9/6558 ,  A61P9/00 ,  C07F9/572 ,  C07D405/10

Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US10717708B2

公开(公告)日：2020-07-21

申请号：US15776933

申请日：2016-12-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nicholas R. Wurtz ,  Pravin Sudhakar Shirude

IPC: C07D401/12 ,  C07D211/76 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D405/10 ,  C07D405/12 ,  C07D409/10 ,  C07D413/10 ,  C07D413/12 ,  C07D417/12

Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US20200207735A1

公开(公告)日：2020-07-02

申请号：US16619960

申请日：2018-06-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pravin Sudhakar Shirude ,  Amit Kumar Chattopadhyay ,  Chandrasekhar Rachamreddy ,  Nicholas R. Wurtz ,  Ellen K. Kick

IPC: C07D401/10 ,  C07D498/08 ,  C07D401/14 ,  C07D413/14 ,  C07D491/107 ,  A61P9/00

Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.

公开(公告)号：US20180327358A1

公开(公告)日：2018-11-15

申请号：US15776933

申请日：2016-12-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Nicholas R. Wurtz ,  Pravin Sudhakar Shirude

IPC: C07D211/76 ,  C07D401/12 ,  C07D401/10 ,  C07D417/12 ,  C07D413/10 ,  C07D405/10 ,  C07D405/12 ,  C07D401/04 ,  C07D409/10 ,  C07D413/12 ,  C07D401/14

Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US20230250063A1

公开(公告)日：2023-08-10

申请号：US18004722

申请日：2021-07-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James A. Johnson ,  Zulan Pi ,  Nicholas R. Wurtz ,  Joanne M. Smallheer ,  Meriah Neissel Valente ,  Ellen K. Kick ,  Charles G. Clark ,  Pravin Sudhaka Shirude ,  Balaji Kumar Seshadri ,  Amit Kumar Chattopadhyay

IPC: C07D231/50 ,  C07D405/14 ,  C07D401/14 ,  C07D451/02 ,  C07D413/14 ,  C07D401/04

CPC classification number: C07D231/50 ,  C07D405/14 ,  C07D401/14 ,  C07D451/02 ,  C07D413/14 ,  C07D401/04

Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US20220298186A1

公开(公告)日：2022-09-22

申请号：US17616748

申请日：2020-06-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pravin Sudhakar Shirude ,  Amit Kumar Chattopadhyay ,  Ellen K. Kick ,  Nicholas R. Wurtz

IPC: C07F9/6558 ,  C07F9/59

Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US11124494B2

公开(公告)日：2021-09-21

申请号：US16619965

申请日：2018-06-08

Applicant: Bristol-Myers Squibb Company

Inventor： Pravin Sudhakar Shirude ,  Amit Kumar Chattopadhyay ,  Nicholas R. Wurtz

IPC: C07D401/12 ,  C07D211/56 ,  C07D413/10

Abstract: The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, and related diseases.

公开(公告)号：US10676431B2

公开(公告)日：2020-06-09

申请号：US16291209

申请日：2019-03-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pravin Sudhakar Shirude ,  Vishweshwaraiah Baligar ,  Balaji Seshadri ,  Amit Kumar Chattopadhyay ,  Nicholas R. Wurtz ,  Ellen K. Kick

IPC: C07D207/14 ,  C07D403/10 ,  C07D401/10 ,  C07D401/12 ,  C07D413/10 ,  C07D409/12 ,  A61P9/04 ,  C07D403/12 ,  C07F9/6558 ,  C07D405/10 ,  C07F9/572 ,  A61P9/00 ,  C07D417/10 ,  C07D413/14 ,  A61P9/10

Abstract: The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.

公开(公告)号：US20200069644A1

公开(公告)日：2020-03-05

申请号：US16612438

申请日：2018-05-22

Applicant: BRISTOL- MYERS SQUIBB COMPANY

Inventor： Jacek Ostrowski ,  Ricardo Garcia ,  Nicholas R. Wurtz ,  Nancy Lersey CARSON

IPC: A61K31/4015 ,  A61K45/06 ,  A61P9/04

Abstract: The disclosure generally relates to methods of treating heart failure with Compound 1, 1-((3S,4R)-4-(2,6-difluoro-4-meth oxyphenyl)-2-oxopyrrolidin-3-yl)-3-phenylurea.

公开(公告)号：US20230348426A1

公开(公告)日：2023-11-02

申请号：US18004731

申请日：2021-07-08

Applicant: Bristol-Myers Squibb Company

Inventor： Pravin Sudhakar Shirude ,  Chandrasekhar Reddy Rachamreddy ,  Amit Kumar Chattopadhyay ,  Balaji Seshadri ,  Vishweshwaraiah Baligar ,  Sudhakara Reddy Madduri ,  Ellen K. Kick ,  Nicholas R. Wurtz

IPC: C07D401/14 ,  C07D401/04 ,  C07D207/14 ,  C07F9/6558 ,  C07D487/08 ,  C07D413/14 ,  C07D405/14 ,  C07D491/107 ,  C07D491/08 ,  C07D403/04 ,  C07D487/04 ,  C07D471/04 ,  C07D498/04 ,  C07F9/572

CPC classification number: C07D401/14 ,  C07D207/14 ,  C07D401/04 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/08 ,  C07D491/107 ,  C07D498/04 ,  C07F9/572 ,  C07F9/65583

Abstract: The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.